Brief: FDA Alerts Health Care Providers, Patients On Increased Risk Of New Blood Cancers With Tazverik Use
May 11 (Reuters) - FDA: FDA: ALERTS HEALTH CARE PROVIDERS AND PATIENTS ABOUT INCREASED RISK OF NEW BLOOD CANCERS WITH TAZVERIK (TAZEMETOSTAT) USE FDA - EXPANDED ACCESS PROGRAMS FOR TAZVERIK WILL BE DISCONTINUED AS WELL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio